Increased expression of TMED2 is an unfavorable prognostic factor in patients with breast cancer

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Yilmaz M, Christofori G. Mechanisms of motility in metastasizing cells. Mol Cancer Res. 2010;8(5):629–642. doi:10.1158/1541-7786.MCR-10-013920460404
   PubMed Web of Science ®Google Scholar
• Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 1998;58(7):1486–1493.9537252
   PubMed Web of Science ®Google Scholar
• Lelekakis M, Moseley JM, Martin TJ, et al. A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis. 1999;17(2):163–170. doi:10.1023/A:100668971950510411109
   PubMed Web of Science ®Google Scholar
• Zakariyah A, Hou W, Slim R, Jerome-Majewska L. TMED2/p24beta1 is expressed in all gestational stages of human placentas and in choriocarcinoma cell lines. Placenta. 2012;33(3):214–219. doi:10.1016/j.placenta.2011.12.00922212250
   PubMed Web of Science ®Google Scholar
• Shi-Peng G, Chun-Lin C, Huan W, et al. TMED2 promotes epithelial ovarian cancer growth. Oncotarget. 2017;8(55):94151–94165. doi:10.18632/oncotarget.2159329212217
   PubMedGoogle Scholar
• Lee GY, Kenny PA, Lee EH, Bissell MJ. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods. 2007;4(4):359–365. doi:10.1038/nmeth101517396127
   PubMed Web of Science ®Google Scholar
• Wu H, Ding Z, Hu D, et al. Central role of lactic acidosis in cancer cell resistance to glucose deprivation-induced cell death. J Pathol. 2012;227(2):189–199. doi:10.1002/path.397822190257
   PubMed Web of Science ®Google Scholar
• Zhang B, Liu Z, Hu X. Inhibiting cancer metastasis via targeting NAPDH oxidase 4. Biochem Pharmacol. 2013;86(2):253–266. doi:10.1016/j.bcp.2013.05.01123688500
   PubMed Web of Science ®Google Scholar
• Li Z, Li AD, Xu L, et al. SPARC expression in gastric cancer predicts poor prognosis: results from a clinical cohort, pooled analysis and GSEA assay. Oncotarget. 2016;7(43):70211–70222. doi:10.18632/oncotarget.1219128053291
   PubMedGoogle Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–15550. doi:10.1073/pnas.050658010216199517
   PubMed Web of Science ®Google Scholar
• Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–658. doi:10.1016/j.neo.2017.05.00228732212
   PubMed Web of Science ®Google Scholar
• Uhlen M, Fagerberg L, Hallstrom BM, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419. doi:10.1126/science.126041925613900
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004;6(1):1–6.15068665
   PubMed Web of Science ®Google Scholar
• Gyorffy B, Lanczky A, Eklund AC, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;123(3):725–731. doi:10.1007/s10549-009-0674-920020197
   PubMed Web of Science ®Google Scholar
• Gyorffy B, Lanczky A, Szallasi Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 2012;19(2):197–208. doi:10.1530/ERC-11-032922277193
   PubMed Web of Science ®Google Scholar
• Szasz AM, Lanczky A, Nagy A, et al. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget. 2016;7(31):49322–49333. doi:10.18632/oncotarget.1033727384994
   PubMedGoogle Scholar
• Gyorffy B, Surowiak P, Budczies J, Lanczky A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. 2013;8(12):e82241. doi:10.1371/journal.pone.008224124367507
   PubMed Web of Science ®Google Scholar
• Pece S, Tosoni D, Confalonieri S, et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell. 2010;140(1):62–73. doi:10.1016/j.cell.2009.12.00720074520
   PubMed Web of Science ®Google Scholar
• Hou W, Gupta S, Beauchamp MC, Yuan L, Jerome-Majewska LA. Non-alcoholic fatty liver disease in mice with heterozygous mutation in TMED2. PLoS One. 2017;12(8):e0182995. doi:10.1371/journal.pone.018299528797121
   PubMed Web of Science ®Google Scholar
• Duquet A, Melotti A, Mishra S, et al. A novel genome-wide in vivo screen for metastatic suppressors in human colon cancer identifies the positive WNT-TCF pathway modulators TMED3 and SOX12. EMBO Mol Med. 2014;6(7):882–901. doi:10.15252/emmm.20130379924920608
   PubMed Web of Science ®Google Scholar
• Vainio P, Mpindi JP, Kohonen P, et al. High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer. PLoS One. 2012;7(6):e39801. doi:10.1371/journal.pone.003980122761906
   PubMed Web of Science ®Google Scholar
• Zheng H, Yang Y, Han J, et al. TMED3 promotes hepatocellular carcinoma progression via IL-11/STAT3 signaling. Sci Rep. 2016;6:37070. doi:10.1038/srep3707027901021
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29. doi:10.3322/caac.2013822237781
   PubMed Web of Science ®Google Scholar
• Santarius T, Shipley J, Brewer D, Stratton MR, Cooper CS. A census of amplified and overexpressed human cancer genes. Nat Rev Cancer. 2010;10(1):59–64. doi:10.1038/nrc277120029424
   PubMed Web of Science ®Google Scholar
• Ohshima K, Hatakeyama K, Nagashima T, et al. Integrated analysis of gene expression and copy number identified potential cancer driver genes with amplification-dependent overexpression in 1,454 solid tumors. Sci Rep. 2017;7(1):641. doi:10.1038/s41598-017-00219-328377632
   PubMed Web of Science ®Google Scholar
• Cuiyan Z, Jie H, Fang Z, et al. Overexpression of RhoE in Non-small Cell Lung Cancer (NSCLC) is associated with smoking and correlates with DNA copy number changes. Cancer Biol Ther. 2007;6(3):335–342. doi:10.4161/cbt.6.3.366317312384
   PubMed Web of Science ®Google Scholar
• Yung MK, Lo KW, Yip CW, et al. Copy number gain of granulin-epithelin precursor (GEP) at chromosome 17q21 associates with overexpression in human liver cancer. BMC Cancer. 2015;15:264. doi:10.1186/s12885-015-1584-325885205
   PubMed Web of Science ®Google Scholar
• Klutstein M, Nejman D, Greenfield R, Cedar H. DNA methylation in cancer and aging. Cancer Res. 2016;76(12):3446–3450. doi:10.1158/0008-5472.CAN-15-327827256564
   PubMed Web of Science ®Google Scholar
• Pan Y, Liu G, Zhou F, Su B, Li Y. DNA methylation profiles in cancer diagnosis and therapeutics. Clin Exp Med. 2018;18(1):1–14. doi:10.1007/s10238-017-0467-028752221
   PubMed Web of Science ®Google Scholar